# US peptide compounding policy in 2026

Canonical: https://europeanpeptideshop.com/blog/hhs-peptide-compounding-policy-2026/

Explore the catalogue and research library. Ordering and shipping have not opened yet.

Research news · 8 November 2026 · 3 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/)

### On this page

HHS has published a draft enforcement policy concerning the compounding of six peptides under section 503A. The notice appeared in the Federal Register on October 30, 2026. The cited notice describes a draft and invites comments; it is not an announcement that FDA has approved six new medicines. [1](https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm)

## Which peptides does the draft name?

Appendix A lists BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. The appendix identifies the substances covered by this particular policy; it is not a list of every compound discussed online as a peptide. [2](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)

Names alone are a poor way to read a regulatory change. Keep three questions separate: which substance is named, which preparation or setting the document addresses, and what action the agency is actually taking.

Question | Where to check

Is a peptide included? | Appendix A and the identity details in Appendix B

What conditions are proposed? | The policy's numbered conditions

Is this a drug approval? | The exact FDA approval record for a finished medicine

[1](https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm) [2](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)

## Who would the policy address?

The notice concerns specified compounding by state-licensed pharmacies, federal facilities and licensed physicians while the 503A bulk-substances list develops through rulemaking. It also says HHS may reconsider the policy if safety or quality problems arise. [1](https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm)

The draft describes conditions including ingredient sourcing, analytical documentation and patient-specific prescribing. Those details matter: a headline about access does not describe every product, seller or route of supply. [2](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)

## How is compounding different from FDA approval?

FDA explains that compounded medicines do not undergo its premarket approval review for safety, effectiveness and quality. Approved generic medicines follow a separate pathway. A policy about enforcement therefore answers a different question from an approval decision for a finished medicine. [3](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers)

This also explains why a laboratory catalogue listing, a pharmacy preparation and an approved drug should not be treated as interchangeable merely because their labels mention the same molecule.

## What should readers watch next?

The notice allows comments for two weeks after publication. Its wording and the current HHS document should be checked again before relying on later headlines. The end of a comment window does not itself show that a final policy has been issued. [1](https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm)

For a useful update, record the document date, version and specific change. A new commentary article, a company announcement and a revised government policy are different events. This page reports the document available on the date above; it does not turn the draft into advice about obtaining or using a peptide.

## Scope for European readers

This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope.

## Laboratory research only

Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here.

## References

- [Federal Register: HHS draft policy notice, October 30, 2026](https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm)

- [HHS peptide enforcement policy and appendices](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)

- [FDA: Compounding and the FDA — questions and answers](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers)

## More articles

Research news · 2 min read

## [UK peptide news: the 2026 timeline](https://europeanpeptideshop.com/blog/peptides-uk-2026-news/)

Peptides UK news in 2026 in date order: from the MHRA clinic probe in April to the Birmingham raid in October, with every source linked.

8 November 2026

Research news · 2 min read

## [Australia's Synedica peptide warning](https://europeanpeptideshop.com/blog/synedica-tga-warning-australia-tb-500/)

Australian testing found Synedica peptide products contained no TB-500 and less retatrutide than labelled. The TGA has told Australians to discard them.

8 November 2026

Research news · 3 min read

## [Avexitide and the LUCIDITY trial](https://europeanpeptideshop.com/blog/avexitide-glp-1-antagonist-lucidity/)

Why does avexitide block GLP-1? Explore post-bariatric hypoglycemia, LUCIDITY results and Amylyx’s November 2026 FDA-filing and conference plans.

8 November 2026